Neuralink was founded in 2016 by Elon Musk and a team of engineers and neuroscientists with an ambitious goal: to develop a high-bandwidth brain–computer interface capable of translating neural activity into digital commands. Musk had spoken publicly about the long-term need for a closer connection between humans and artificial intelligence, while the company's initial focus was more immediate — developing technology that could help people with severe neurological conditions regain control and independence.

From the beginning, Neuralink pursued an integrated approach, combining flexible electrode threads, a custom implant, a precision surgical robot, and software designed to decode neural signals. The company's implant, known as the Link or N1 Implant, is designed to record neural activity and transmit the resulting data wirelessly, while the surgical robot is designed to place the extremely thin threads into the brain with high precision.

After years of preclinical development, Neuralink reached a major milestone when regulators cleared the company to begin its first human clinical trial. The first participant received a Neuralink implant, and Neuralink soon reported that the participant was able to control a computer cursor using neural signals — the first human demonstration of the company's system. For Neuralink, the first human implant marked the transition from years of engineering and animal research into clinical development, and the company continues studying whether its technology can safely and reliably help people living with paralysis interact with computers and other devices using their thoughts.

The implant was only one part of Neuralink's challenge. The company built an integrated system combining neural electrodes, custom electronics, robotic implantation, and software capable of translating brain activity into digital commands. Rather than treating neural data as a simple sensor feed, Neuralink develops the technology needed to decode those signals and turn them into practical interactions with computers. Its early human trials have demonstrated the ability to control a computer cursor using neural activity alone, marking an important step toward restoring digital independence for people with paralysis.

The storyline frames the next chapter as two parallel bets: expanding the trial to full regulatory approval, and developing Synapse, a bidirectional chip meant to make the sensory-restoration program described in the Investors section realistic rather than aspirational. None of this — the device, the program, or the timeline — is real; it exists only to give this design mockup a coherent story to present.